NYSEMKT: NBYNovabay Pharmaceuticals Inc Stock
$0.60+0.00 (+0%)
Updated Jun 16, 2025
NBY Price
$0.60
Fair Value Price
N/A
Market Cap
$3.49M
52 Week Low
$0.36
52 Week High
$2.63
P/E
0.66x
P/B
0.57x
P/S
0.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.15M
Earnings
$3.66M
Gross Margin
65.6%
Operating Margin
51.2%
Profit Margin
37.1%
Debt to Equity
0.6
Operating Cash Flow
-$5M
Beta
0.45
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NBY Overview
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NBY's potential to beat the market
- NBY doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NBY
RankedUnranked of 466
RankedUnranked of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.14 | A | |
| $41.75 | A | |
| $23.67 | A |
Be the first to know about important NBY news, forecast changes, insider trades & much more!
NBY News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NBY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBY is good value based on its earnings relative to its share price (0.66x), compared to the US market average (29.27x)
P/E vs Market Valuation
NBY is good value based on its earnings relative to its share price (0.66x), compared to the US Biotechnology industry average (-111.35x)
P/E vs Industry Valuation
NBY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more NBY due diligence checks available for Premium users.
Valuation
NBY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.66x
Industry
-111.35x
Market
29.27x
NBY is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NBY is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NBY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.57x
Industry
4.59x
NBY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NBY's financial health
Profit margin
Revenue
$0.0
Net Income
$7.7M
Profit Margin
0%
NBY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NBY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.9M
Liabilities
$3.7M
Debt to equity
0.6
NBY's short-term assets ($9.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBY's short-term assets ($9.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NBY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.3M
Investing
$0.0
Financing
-$1.7M
NBY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBY vs Biotech Stocks
Novabay Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.